The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma
Molecular Carcinogenesis · 2024
DOI: 10.1002/mc.23769 ↗At a glance
Journal article in Molecular Carcinogenesis, 2024. Written by Shuwen Kuang and 6 co-authors. Institution: Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical …. Major MEDLINE topics: Carcinoma, Hepatocellular, Phenylurea Compounds, Pyridines, Liver Neoplasms. Cited 7 times so far (Crossref); 47 references. Funded by: National Natural Science Foundation, Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS), CSCO-Bayer Research Foundation of Cancer.
Abstract (original language)
Regorafenib is a second‐line standard treatment for hepatocellular carcinoma (HCC). However, the efficacy of regorafenib is often limited due to drug resistance, individual differences among patients, and irrational drug use. Radiotherapy (RT) is an important method of localized HCC treatment, and combining RT with other therapies may exert a synergetic antitumor effect. Platelet‐derived growth factor receptor‐like (PDGFRL) is a tumor suppressor in various solid tumors. However, the function of PDGFRL in HCC is still unknown. In this study, we explored whether regorafenib and RT exert a synergetic effect on the treatment of HCC. The antitumor effect and mechanisms of the combination of regorafenib and RT were verified in a xenograft mouse model in vivo and in HCC cells in vitro. The combination treatment significantly inhibited cell proliferation and promoted apoptosis both in vitro and in vivo. PDGFRL, a potential target of regorafenib, was increased after cumulative treatment in HCC cells, and PDGFRL suppressed HCC cell proliferation and promoted apoptosis by inhibiting STAT3 pathway activation. Furthermore, the cumulative antitumor effect was dependent on the upregulated expression of PDGFRL and inhibition of STAT3 signaling pathway activation in HCC cells. This study increased the understanding of the molecular mechanism underlying the effect of regorafenib plus RT on HCC and provided a theoretical basis for the clinical practice of HCC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Laboratory of Cell and Molecular Biology & State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking…
ORCID profiles: Mei Liu
Funding
- National Natural Science Foundation
- Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS)
- CSCO-Bayer Research Foundation of Cancer
Cite
APA
Kuang, S., Zhang, J., Huang, N., Zhang, J., Chen, B., Wang, L., & Liu, M. (2024). The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23769
Vancouver
Kuang S, Zhang J, Huang N, Zhang J, Chen B, Wang L, et al. The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23769
BibTeX
@article{Kuang2024,
author = {Kuang, Shuwen and Zhang, Jiajun and Huang, Ning and Zhang, Jing and Chen, Bo and Wang, Liming and Liu, Mei},
title = {The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma},
journal = {Molecular Carcinogenesis},
year = {2024},
doi = {10.1002/mc.23769}
}
EUVIMED